Determinants of Myelosuppression in the Treatment of Non-small Cell Lung Cancer with Cisplatin-containing Chemotherapy
Open Access
- 1 July 1996
- journal article
- clinical trial
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 87 (7), 781-786
- https://doi.org/10.1111/j.1349-7006.1996.tb00292.x
Abstract
Data on 16 potential risk factors for myelosuppression were assessed in 134 patients who received either vindesine and cisplatin (VP) or mitomycin C, vindesine and cisplatin (MVP) for inoperable stage III or IV non‐small cell lung cancer in a randomized trial. Determinant factors for myelosuppression were evaluated by using univariate analysis and the logistic regression model. Recursive partitioning and amalgamation (RPA) was also used to define patient subgroups frequently suffering from severe bone marrow toxicity. Overall, 33 (25%) of 134 patients experienced at least one episode of grade 4 leukopenia. In univariate analysis, age, body surface area, serum creatinine, and pretreatment hemoglobin concentration were associated with severe leukopenia. A multivariate analysis using the logistic regression method showed that only raised creatinine level was an independent predictor for grade 4 leukopenia (P=0.049). The RPA model generated three distinct subgroups based on age, body surface area and regimen. The three subgroups were distinguished by the frequency of severe (grade 4) leukopenia (50%, 25%, and 2.4%, respectively) (P<0.001). Grade 4 leukopenia occurred more frequently in patients in class 3 (age ≥65 years and treatment with MVP). The RPA model was useful in identifying the risk factors for myelosuppression induced by cisplatin‐based chemotherapy, and in defining patient subgroups with elevated risk of toxicity.Keywords
This publication has 16 references indexed in Scilit:
- The Aged Patient with Lung CancerDrugs & Aging, 1994
- Aging and Marrow Neutrophil ReservesJournal of the American Geriatrics Society, 1994
- Metastatic non-small cell lung cancerLung Cancer, 1993
- Mitomycin C, Vindesine, and Cisplatin in Advanced Non-Small-Cell Lung Cancer A Phase II StudyAmerican Journal of Clinical Oncology, 1992
- A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinomaCancer, 1991
- A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.Journal of Clinical Oncology, 1991
- Pharmacology of antineoplastic agents in the elderly patient.1989
- National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐makingJournal of the American Geriatrics Society, 1988
- Recursive Partition: A Versatile Method for Exploratory-Data Analysis in BiostatisticsPublished by Springer Science and Business Media LLC ,1987
- Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.1986